Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.73 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.65 |
| ▸ | TUBB | P07437 | 1/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.65 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.65 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.65 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.65 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.65 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 2/20 | 0.65 |
| ▸ | CNR2 | P34972 | 1/20 | 0.65 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16345708 | 0.95 | ESR1 (0.67) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL18319214 | 0.95 | ESR1 (0.67) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL6980679 | 0.92 | ESR1 (0.71) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL6967393 | 0.92 | ESR1 (0.71) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7958236 | 0.92 | ESR1 (0.64) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL23113126 | 0.91 | ESR1 (0.70) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL8519077 | 0.91 | ESR1 (0.70) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL5026252 | 0.90 | CNR1 (0.78) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7671512 | 0.90 | ESR1 (0.69) | ESR1ESR2TUBB4ATUBBTUBA3C | |
| SCHEMBL7665777 | 0.90 | ESR1 (0.69) | ESR1ESR2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6090843-A | POSTMENOPAUSE DISEASES; ESTROGEN SENSITIVITY; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | claimed |
| EP-0902025-A2 | Benzothiophenes for treatment of estrogen related conditions | ELI LILLY AND COMPANY (US) | 1999-03-17 | — | — | EP | claimed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-04-20 | — | — | US | disclosed |
| EP-3793608-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-6291484-B1 | TREATMENT OF THE VARIOUS MEDICAL CONDITIONS ASSOCIATED WITH POSTMENOPAUSAL SYNDROME | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| US-6090843-A | POSTMENOPAUSE DISEASES; ESTROGEN SENSITIVITY; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0902025-A2 | Benzothiophenes for treatment of estrogen related conditions | ELI LILLY AND COMPANY (US) | 1999-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | ESR1 31/4885ESR2 14/4885TUBB4A 1397/4885 |
| US-20230122310-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | ESR1 31/4885ESR2 14/4885TUBB4A 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.